Are they asleep at the wheel?, page-8

Your vote is a waste of time. They have a product on the verge of IND and a trial about to start. The options have been allowed to lapse as they should. The next CR was always going to be around this price.... plus or minus. The plus could be a well designed trial, the minus, something average. Smart money has known this longer than I've been telling the forum. All I got was 'this is going to the moon' posts. She has done well over the years with a product that is weak against HCV. It had to happen this way. There are not enough funds to get into another drug in a big way and all the eggs are in the HIV basket right now. The best thing is that the IND will be just as good for HIV..... although it has been proven on HCV. I doubt anyone here bar a couple have any idea how difficult it is to produce an IND for the FDA. The next trial after this one being planned now, will be in the US and probably in dual infected HIV patients. I think the board know where they are at and have done for a while. They are quiet because the options must die quietly and they must organise a new CR. A deal did not eventuate, that was the only hope for the options. Hers will expire worthless too.

Trial announcement very soon.